Cargando…
KIAA1522 potentiates TNFα-NFκB signaling to antagonize platinum-based chemotherapy in lung adenocarcinoma
BACKGROUND: The platinum-based chemotherapy is the first-line regimen for the treatment of Non-small cell lung cancer (NSCLC). However, the therapeutic efficiency is largely limited by tenacious chemo-insensitivity that results in inferior prognosis in a cohort of patients. It has been known that KI...
Autores principales: | Wang, Boshi, Jing, Tiantian, Jin, Weilin, Chen, Jinnan, Wu, Chengsi, Wang, Mingrong, Liu, Yizhen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450600/ https://www.ncbi.nlm.nih.gov/pubmed/32854746 http://dx.doi.org/10.1186/s13046-020-01684-x |
Ejemplares similares
-
Poor Prognostic Biomarker KIAA1522 Is Associated with Immune Infiltrates in Hepatocellular Carcinoma
por: Shi, Yongjie, et al.
Publicado: (2023) -
High KIAA1522 expression predicts a poor prognosis in patients with hepatocellular carcinoma
por: Xu, Yongzheng, et al.
Publicado: (2020) -
The Prognostic Significance of KIAA1522 Expression in Non-Small-Cell Lung Cancer Patients
por: Özdede, Murat, et al.
Publicado: (2023) -
KIAA1522 is a novel prognostic biomarker in patients with non-small cell lung cancer
por: Liu, Yi-Zhen, et al.
Publicado: (2016) -
KIAA1522 overexpression promotes tumorigenicity and metastasis of esophageal cancer cells through potentiating the ERK activity
por: Xie, Zhi-Hui, et al.
Publicado: (2017)